Navigation Links
PEAK Surgical, Inc. Closes $21 Million Series C Financing
Date:2/4/2008

- Joyce Erony Joins Board of Directors -

PALO ALTO, Calif., Feb. 4 /PRNewswire/ -- PEAK Surgical, Inc., a medical device company that is developing a new category of tissue dissection systems based on a proprietary technology, today announced that it has raised $21 million in a Series C financing led by new investor Signet Healthcare Partners. The company also announced that Joyce Erony, managing director of Signet Healthcare Associates, has joined PEAK Surgical's board of directors. Existing investors Lehman Brothers and Venrock Associates also participated in this financing round.

"The size, valuation and timing of this financing validates the progress we have made in advancing our pulsed plasma technology and developing our flagship product, the PEAK Surgery System," said John Tighe, president and chief executive officer of PEAK Surgical. "This financing allows us to aggressively pursue the development plan and commercialization efforts for our PEAK Surgery System, which we believe represents a quantum leap over surgical instruments in use today and will revolutionize the way surgery is performed. We believe it may have applications in more than 2 million surgical procedures."

The PEAK(TM) Surgery System includes the PEAK PlasmaBlade(TM), a disposable cutting tool that offers the exacting control of a scalpel and the bleeding control of traditional electrosurgery without the extensive collateral damage. PEAK Surgical has filed a pre-market notification (510k) with the U.S. Food and Drug Administration (FDA) for the PEAK Surgery System. The company also has started setting up manufacturing for the PEAK PlasmaBlade and is establishing a national sales force to distribute the device once the 510k has been cleared by the FDA.

"PEAK Surgical has the financial foundation, management team and technology platform in place to ensure rapid development of its next-generation tissue dissection system," Erony said. "We believe PEAK Surgical's pulsed plasma technology has broad applicability across numerous surgical fields and that the PEAK PlasmaBlade may offer a new alternative for surgeons to provide better outcomes for their patients, including reduced scarring and faster recovery."

PEAK Surgical has raised more than $29 million to date in three rounds of private financing.

About PEAK Surgical, Inc.

PEAK Surgical, Inc. is a medical device company that is developing a new category of tissue dissection systems based on a proprietary technology. PEAK's flagship product in development, the PEAK(TM) Surgery System, combines the PULSAR(TM) Generator, which supplies unrivaled pulsed plasma radiofrequency energy, with the PEAK PlasmaBlade(TM), a disposable cutting tool that offers the exacting control of a scalpel and the bleeding control of traditional electrosurgery without the extensive collateral damage. The company is exploring the applicability of this technology across numerous surgical fields, including general, cardiac, gynecologic, plastic and neuro surgery. For more information, please visit http://www.peaksurgical.com.


'/>"/>
SOURCE PEAK Surgical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ascension Orthopedics Closes $21 Million Financing and Recruits an Orthopedics Industry Veteran as CEO
2. Synergy Life Science Partners Closes $143M Debut Medical Device Fund
3. MM2 Group Closes Sale for New Fish Oil Product
4. NutraDyne, Inc. Closes Amended Exchange Agreement With Changchun Yongxin Dirui Medical Co., Ltd.
5. MM2 Group Closes $1.1 Million Sale
6. Danaher Closes Subsequent Offering Period for Tektronix; Acquires Over 90% of TEK Shares
7. BCP Veterinary Pharmacy Helps Cure Diabetic Cats with BCP PZI(R), the Closest Match to Feline Insulin Available
8. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
9. Pfizer Closes La Jolla Campus Due to Continuing Fire Emergency
10. Nexia Closes Acquisition of Green Endeavors; Landis Salons On Track to Generate Revenues of $2.2 Million in 2007
11. MediKeeper Closes Series A Financing Round with PacifiCap as Lead Investor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... (PRWEB) , ... July 19, 2017 , ... ... a $1.5 million Health Resources and Services Administration (HRSA) grant to train predoctoral ... special health care needs in rural and underserved areas. , The Predoctoral Pediatric ...
(Date:7/20/2017)... ... 19, 2017 , ... A July 7th article ... varicose veins in some patients, according to medical experts. Washington State medical clinic ... excessive sitting or standing, or regularly nicking yourself while shaving your legs, and ...
(Date:7/18/2017)... ... 18, 2017 , ... CannaKids, a California Cooperative Cooperation that specializes in the ... the WORLDZ Summit, taking place in Hollywood from July 31-August 1, the Company’s ... cannabis for both pediatric and adult patients, and how the path has led her ...
(Date:7/18/2017)... ... July 18, 2017 , ... The results of an international clinical trial, led in part by ... severe type of muscular dystrophy holds promise for a subgroup of patients. , In a ... and colleagues at 53 study sites in 18 countries describe the clinical benefit of using ...
(Date:7/18/2017)... ... July 18, 2017 , ... An inventor from Seattle, Wash., has developed ... to clean, scrub and moisturize the back and other hard-to-reach areas of the body. ... movement in my upper body, particularly my shoulders. I found it difficult to reach ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Corp., also known as ,The Epigenetics Company, announced today the release of ... using the myDNAge ™ test. Based on Horvath,s Clock, so named ... biostatistics at the David Geffen School of Medicine at UCLA ... ™ technology is used to analyze DNA methylation patterns of over ... Epigenetic ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... TRIANGLE PARK, N.C. , July 10, 2017 /PRNewswire/ ... a $5m Convertible Note to support the development of ... by Tencent Holdings Limited, a leading Chinese Internet services ... This funding will advance multiple infectious disease product programs ... Founded by Dr. ...
Breaking Medicine Technology: